US Patent Issued to QATAR UNIVERSITY on Sept. 16 for "GATA3 inhibitors for treating insulin resistance" (Qatari Inventors)

ALEXANDRIA, Va., Sept. 17 -- United States Patent no. 12,416,007, issued on Sept. 16, was assigned to QATAR UNIVERSITY (Doha, Qatar).

"GATA3 inhibitors for treating insulin resistance" was invented by Mohamed Elrayess (Doha, Qatar) and Layla Almansoori (Doha, Qatar).

According to the abstract* released by the U.S. Patent & Trademark Office: "Methods and compositions using dnayzme-based GATA3 inhibitors for the treatment of insulin resistance and Type II diabetes, for the stimulation of adipogenesis in vivo, and for the promotion of fat redistribution are disclosed."

The patent was filed on May 19, 2023, under Application No. 18/199,817.

*For further information, including images, charts and tables, please visit: http://patft.uspto.gov/n...